Celldex Therapeutics (CLDX)
Drug: CDX-110 (PF-04948568)
Abstract No.2014Indication: Glioblastoma (brain tumor) Clinical Trial: Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide in patients with glioblastoma (GBM). Presentation Time: Saturday, June 5. Poster session. Notes:Thursday's research abstract reports efficacy results on the first 40 patients enrolled. Twenty-eight of 40 patients, or 70%, are progression free at 5.5 months of follow up. One patient reported a serious hypersensitivity reaction to the CDX-110 injections that required discontinuation from the study. The abstract also states that an additional, placebo-controlled study of CDX-110 will likely be required. Celldex's CDX-110, partnered with Pfizer, is engineered to activate a patient's immune system to fight cancer. Interest in so-called cancer "vaccines" is increasing as Dendreon (DNDN) awaits FDA approval of its prostate cancer immunotherapy Provenge.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV